The AACR editors are proud to present this selection of impactful journal articles focusing on lung cancer, published from across the AACR journal portfolio.
- Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance.
Jeong Y Diehn M. Cancer Discovery January 2017.
- Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer.
Zhang H Wong K. Cancer Discovery September 2016.
- The impact of preexisting mental health disorders on the diagnosis, treatment, and survival among lung cancer patients in the U.S. military health system.
Lin J Zhu K. Cancer Epidemiology, Biomarkers & Prevention December 2016.
- Fixed-dose combinations of pioglitazone and metformin for lung cancer prevention.
Seabloom DE Ondrey FG. Cancer Prevention Research February 2017.
- A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma.
Kaufman JM Carbone DP. Cancer Research January 2017.
- Molecular evolution patterns in metastatic lymph nodes reflect the differential treatment response of advanced primary lung cancer.
Um SW Park WY. Cancer Research November 2016.
- A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a Phase II Trial.
Yanagita M Janne PA. Clinical Cancer Research December 2016.
- Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer.
Mustachio LM Dmitrovsky E. Molecular Cancer Research January 2017.
- Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer.
Miyawaki M Soejima K. Molecular Cancer Research January 2017.
- AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients.
Xu X Zhang L. Molecular Cancer Therapeutics November 2016.
- Development of a novel antibody–drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1.
Thomas LJ Keler T. Molecular Cancer Therapeutics December 2016.